HomeCompareEARS vs STAG

EARS vs STAG: Dividend Comparison 2026

EARS yields 65.68% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EARS wins by $839.2K in total portfolio value
10 years
EARS
EARS
● Live price
65.68%
Share price
$3.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$857.5K
Annual income
$214,640.91
Full EARS calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — EARS vs STAG

📍 EARS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEARSSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EARS + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EARS pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EARS
Annual income on $10K today (after 15% tax)
$5,582.92/yr
After 10yr DRIP, annual income (after tax)
$182,444.77/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, EARS beats the other by $182,051.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EARS + STAG for your $10,000?

EARS: 50%STAG: 50%
100% STAG50/50100% EARS
Portfolio after 10yr
$437.9K
Annual income
$107,551.56/yr
Blended yield
24.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

EARS
No analyst data
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EARS buys
0
STAG buys
0
No recent congressional trades found for EARS or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEARSSTAG
Forward yield65.68%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$857.5K$18.3K
Annual income after 10y$214,640.91$462.22
Total dividends collected$722.8K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: EARS vs STAG ($10,000, DRIP)

YearEARS PortfolioEARS Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$17,268$6,568.14$10,665$345.09+$6.6KEARS
2$29,077$10,599.97$11,364$357.70+$17.7KEARS
3$47,793$16,681.04$12,098$370.43+$35.7KEARS
4$76,764$25,624.68$12,869$383.28+$63.9KEARS
5$120,602$38,464.70$13,677$396.23+$106.9KEARS
6$185,521$56,477.71$14,524$409.27+$171.0KEARS
7$279,704$81,195.93$15,411$422.41+$264.3KEARS
8$413,691$114,407.58$16,339$435.61+$397.4KEARS
9$600,792$158,142.40$17,311$448.89+$583.5KEARS
10$857,488$214,640.91$18,327$462.22+$839.2KEARS

EARS vs STAG: Complete Analysis 2026

EARSStock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Full EARS Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this EARS vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EARS vs SCHDEARS vs JEPIEARS vs OEARS vs KOEARS vs MAINEARS vs PLDEARS vs EQREARS vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.